Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first- line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II

被引：10

作者：

Duhoux, Francois P.

Jager, Agnes

Dirix, Luc Yves

Huizing, Manon Thirza

Jerusalem, Guy Heinrich Maria

Vuylsteke, Peter

De Cuypere, Eveline

Breiner, Doris

Mueller, Christian

Brignone, Chrystelle

Triebel, Frederic

机构：

[1] Clin Univ Saint Luc, King Albert II Canc Inst, Dept Med Oncol, Brussels, Belgium

[2] Catholic Univ Louvain, Inst Rech Experimentale & Clin Pole MIRO, Brussels, Belgium

[3] Erasmus MC Canc Inst, Rotterdam, Netherlands

[4] GZA St Augustinus, Oncol Cent GZA, TCRU, Antwerp, Belgium

[5] Univ Antwerp Hosp, Edegem, Belgium

[6] Univ Liege, Liege, Belgium

[7] CHU Sart Tilman Liege, Liege, Belgium

[8] Catholic Univ Louvain, CHU UCL Namur, Namur, Belgium

[9] Gen Hosp AZ Sint Jan Brugge Oostende, Brugge, Belgium

[10] Immutep, Clin Dev, Berlin, Germany

[11] Immutep, Res & Dev, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.1050

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1050

引用

页数：2

共 50 条

[41] Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors
Majem, M.
Forster, M. D.
Krebs, M. G.
Peguero, J.
Clay, T. D.
Felip, E.
Iams, W.
Roxburgh, P.
de Speville, B. Doger
Bajaj, P.
Mueller, C.
Triebel, F.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S43 - S44
[42] A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
Dieras, V.
Jassem, J.
Dirix, L. Y.
Guastalla, J. P.
Bono, P.
Hurvitz, S. A.
Goncalves, A.
Romieu, G.
Limentani, S. A.
Jerusalem, G. H. M.
Lakshmaiah, K.
Roche, H. H.
Sanchez-Rovira, P.
Pienkowski, T.
Segui-Palmer, M. A.
Li, A.
Sun, Y.
Pickett-Gies, C. A.
Wildiers, H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[43] A PHASE II STUDY (TACTI-002) OF EFTILAGIMOD ALPHA (A SOLUBLE LAG-3 PROTEIN) WITH PEMBROLIZUMAB IN PD-L1 UNSELECTED PATIENTS WITH METASTATIC NON-SMALL CELL LUNG(NSCLC) OR HEAD AND NECK CARCINOMA(HNSCC)
Krebs, Matthew
Majem, Margarita
Felip, Enriqueta
Forster, Martin
Doger, Bernard
Clay, Tim
Carcereny, Enric
Peguero, Julio
Horn, Leora
Bajaj, Pawan
Roxburgh, Patricia
Brignone, Chrystelle
Mueller, Christian
Triebel, Frederic
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A472 - A473
[44] Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)
Carcereny, E.
Felip, E.
Majem, M.
Doger de Speville, B.
Clay, T. D.
Bondarenko, I.
Peguero, J.
Dols, M. Cobo
Forster, M. D.
Ursol, G.
Kalinka, E.
Garcia Ledo, G. M.
Vila Martinez, L.
Iams, W.
Krebs, M. G.
Kefas, J.
Efthymiadis, K.
Perera, S.
Mueller, C.
Triebel, F.
ANNALS OF ONCOLOGY, 2023, 34
[45] Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first- line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Miles, D. W.
Gligorov, J.
Andre, F.
Cameron, D.
Schneeweiss, A.
Barrios, C. H.
Xu, B.
Wardley, A. M.
Kaen, D.
Andrade, L.
Semiglazov, V.
Reinisch, M.
Patre, M.
Morales, L.
Russell, K.
Donica, M.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2020, 31 : S1147 - S1148
[46] Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination with Taxane chemotherapy in metastatic breast cancer (MBC)
Mariotti, Veronica
Tang, Shou-Ching
Dillon, Patrick
Montero, Alberto
Poklepovic, Andrew
Melin, Susan
Nuhad, Ibrahim
Nikolinakos, Petros
Kennedy, Eugene
Han, Hyo
Ismail-Khan, Roohi
Bruetman, Daniel
Danciu, Oana
Gilman, Paul
Karaszewska, Boguslawa
Lesniewski-Kmak, Krzysztof
Panella, Timothy
Patel, Dhimant
Suszko-Kazarnowicz, Malgorzata
Volterra, Fabio
Soliman, Hatem
CANCER RESEARCH, 2020, 80 (04)
[47] Biomarker (BM) results from MERiDiAN, a double-blind placebo (PLA)-controlled randomized phase 3 trial of 1st-line paclitaxel (PAC) with or without bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC)
Das Thakur, M.
Bais, C.
Estay, I.
Vaidyanathan, R.
O'Shaughnessy, J.
Cameron, D.
Hubeaux, S.
Quah, C.
Miles, D.
CANCER RESEARCH, 2016, 76
[48] LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).
Kim, Sung-Bae
Tan, Antoinette R.
Im, Seock-Ah
Villanueva, Rafael
Valero, Vicente
Saura, Cristina
Oliveira, Mafalda
Isakoff, Steven J.
Singel, Stina Mui
Dent, Rebecca Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[49] Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a Randomized, Multicenter, Open-Label, Phase II Study of the Dutch Breast Cancer Trialists' Group (BOOG).
Lam, S. W.
de Groot, S. M.
Honkoop, A. H.
Jager, A.
ten Trje, A. J.
Bos, M. M. E. M.
Linn, S. C.
van den, Bosch J.
Nortier, J. W. R.
Braun, J. J.
de Graaf, H.
Portielje, J. E. A.
Los, M.
Gooyer, D. D.
van Tinteren, H.
Boven, E.
CANCER RESEARCH, 2011, 71
[50] AIPAC (Active Immunotherapy PAClitaxel): A phase IIb trial in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a standard chemotherapy regimen of paclitaxel
Mueller, C.
Triebel, F.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →